These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

540 related items for PubMed ID: 25914541

  • 1. Alogliptin benzoate for management of type 2 diabetes.
    Saisho Y.
    Vasc Health Risk Manag; 2015; 11():229-43. PubMed ID: 25914541
    [Abstract] [Full Text] [Related]

  • 2. Alogliptin: safety, efficacy, and clinical implications.
    Marino AB, Cole SW.
    J Pharm Pract; 2015 Feb; 28(1):99-106. PubMed ID: 24532820
    [Abstract] [Full Text] [Related]

  • 3. Alogliptin; a review of a new dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes mellitus.
    Said S, Nwosu AC, Mukherjee D, Hernandez GT.
    Cardiovasc Hematol Disord Drug Targets; 2014 Feb; 14(1):64-70. PubMed ID: 24993124
    [Abstract] [Full Text] [Related]

  • 4. Alogliptin benzoate for the treatment of type 2 diabetes.
    Rendell M, Drincic A, Andukuri R.
    Expert Opin Pharmacother; 2012 Mar; 13(4):553-63. PubMed ID: 22296609
    [Abstract] [Full Text] [Related]

  • 5. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin.
    Capuano A, Sportiello L, Maiorino MI, Rossi F, Giugliano D, Esposito K.
    Drug Des Devel Ther; 2013 Mar; 7():989-1001. PubMed ID: 24068868
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes.
    Scheen AJ.
    Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):1005-20. PubMed ID: 25936384
    [Abstract] [Full Text] [Related]

  • 15. Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
    Pratley RE.
    Expert Opin Pharmacother; 2009 Feb; 10(3):503-12. PubMed ID: 19191685
    [Abstract] [Full Text] [Related]

  • 16. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.
    Deacon CF.
    Curr Opin Investig Drugs; 2008 Apr; 9(4):402-13. PubMed ID: 18393107
    [Abstract] [Full Text] [Related]

  • 17. Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.
    Triplitt C, Cersosimo E, DeFronzo RA.
    Vasc Health Risk Manag; 2010 Sep 07; 6():671-90. PubMed ID: 20859539
    [Abstract] [Full Text] [Related]

  • 18. Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.
    Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H.
    Br J Pharmacol; 2009 Jun 07; 157(3):415-26. PubMed ID: 19371350
    [Abstract] [Full Text] [Related]

  • 19. [Alogliptin (Vipidia): a selective DPP-4 inhibitor with a good cardiovascular safety].
    Scheen AJ.
    Rev Med Liege; 2014 Jun 07; 69(7-8):460-6. PubMed ID: 25158388
    [Abstract] [Full Text] [Related]

  • 20. The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus.
    Dudkowski C, Tsai M, Liu J, Zhao Z, Schmidt E, Xie J.
    Eur J Clin Pharmacol; 2017 Mar 07; 73(3):279-288. PubMed ID: 27999883
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.